Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Local Expertise, Growing Oncology Market Behind Lilly/Innovent Deal

This article was originally published in PharmAsia News

Executive Summary

The deal just signed between Lilly and Innovent is one of the most wide-ranging so far between a US pharma major and a Chinese biotech, and has the dual attractions of accessing both local capabilities and the growing oncology market in China.

Advertisement

Related Content

China's Innovent Biologics Emerges As Immuno-Oncology Competitor With Sintilimab Approval

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC088725

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel